ポマリスト®カプセルの安全性と有効性：1mg、2mg、3mg、または4mgの用量でポマリスト®を投与されたすべての患者における実際の使用状況

基本情報

NCT ID

NCT02921828

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

1,149

治験依頼者名

Celgene

概要

1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form of the surveillance will be completed at the time when the planned number of patients to be enrolled is reached. During a period until conditions for approval are removed, a system enabling to retrospectively collect appropriate information based on patient data from RevMate® will be, as necessary, maintained. 2. Planned duration of the surveillance Anticipated to be 2 years and 6 months from the start date of release of Pomalyst

対象疾患

依頼者（Sponsor）

実施施設 (1)